Author:
Rocca Andrea,Cecconetto Lorenzo,Passardi Alessandro,Melegari Elisabetta,Andreis Daniele,Monti Manuela,Maltoni Roberta,Sarti Samanta,Pietri Elisabetta,Schirone Alessio,Fabbri Francesco,Donati Caterina,Nanni Oriana,Fedeli Anna,Faedi Marina,Amadori Dino
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference36 articles.
1. GLOBOCAN 2012: Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013.
http://globocan.iarc.fr
. Accessed on 28 May 2016
2. Prat A, Perou CM (2011) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5:5–23
3. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792
5. Yeo B, Kotsori K, Mohammed K, Walsh G, Smith IE (2015) Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab. Breast 24:751–757
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献